Azzad Asset Management’s Lipocine LPCN Stock Holding History

Azzad Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-882	Closed	-$4.77K	–	326
2023 Q1	$4.77K	Buy	+882	New	+$6.81K	﹤0.01%	317

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Azzad Asset Management's LPCN Position: Q2 2023 in Review

Azzad Asset Management sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 882 shares — an estimated $4.77K sold.

Azzad Asset Management first reported a position in LPCN in Q1 2023 and held it in 1 quarter. The position peaked at $4.77K in Q1 2023. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

Azzad Asset Management reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
Azzad Asset Management sold 882 Lipocine shares in Q2 2023, an estimated $4.77K.
Azzad Asset Management first reported a position in Lipocine in Q1 2023 and held it in 1 quarter.
Azzad Asset Management's Lipocine position peaked at $4.77K in Q1 2023.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Azzad Asset Management's 13F filing for Q2 2023, filed 1 Apr 2024.